CorMedix
CorMedix's revenue rose 617.0% to $312 million in fiscal 2025. Its operating margin was 48.2%, up from −51.4% a year earlier. Free cash flow was $173 million. The diluted share count rose 36.4%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What CorMedix does
CorMedix sells drugs for life-threatening infections and conditions, mainly in hospitals and dialysis clinics. Its first product, DefenCath, is a lock solution placed in a catheter to reduce bloodstream infections in adults with kidney failure who get hemodialysis through a central venous catheter. The FDA approved it in November 2023, it launched in 2024, and it is the largest contributor to the company's net sales.
In August 2025 CorMedix bought Melinta Therapeutics, which added six marketed infection-fighting products sold to hospitals and clinics, among them REZZAYO, MINOCIN IV and VABOMERE, plus a heart drug, TOPROL-XL. The company focuses its promotion on DefenCath, REZZAYO, MINOCIN IV and VABOMERE.
It sells DefenCath to dialysis organizations under multi-year supply agreements. It is also seeking approval to use DefenCath in adults receiving nutrition through a vein, and to use REZZAYO to prevent fungal infections in patients with weakened immune systems. It says it also looks for deals that fit its sales team.
Its biggest risks, as it describes them
- It has a history of operating losses and may not stay profitable, even though it earned a profit in 2025.
- It depends on selling and winning insurance reimbursement for DefenCath and its other products in the U.S.
- Its expansion into new uses for DefenCath and REZZAYO may not win FDA approval.
- The Melinta purchase may not bring the benefits it expects.
- It needs enough funding and manufacturing and sales arrangements to grow.
Income statement
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 66 | 59 | 76 | 52 | 148 |
| Debt incl. finance leases | — | — | — | — | 1 |
| Net debt (negative means net cash) | — | — | — | — | −147 |
| Net debt to EBITDA | — | — | — | — | −0.9x |
| Debt to equity | — | — | — | — | 0.0x |
| Interest coverage | −1,846.4x | −1,155.0x | −1,427.5x | −621.0x | 54.0x |
| Current ratio | 12.4x | 9.4x | 7.0x | 3.4x | 2.1x |
| Quick ratio | 12.4x | 9.4x | 6.8x | 3.2x | 1.9x |
Cash flow
Projections
Project CorMedix's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What CorMedix says to expect
- Full year 2026: revenue, EBITDA and operating costs
The Company maintains full-year 2026 consolidated revenue guidance of $325 to $345 million, narrows full-year adjusted EBITDA guidance to a range of $130 to $140 million from a range of $125 to $140 million, and reduces cash-based OpEx guidance to a range of $140 to $145 million from $145 to $155 million.
Insider trades
No officer, director or 10% owner of CorMedix reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | — | — | 672.5% |
| Altman Z'' | −5.17 | −3.52 | 3.07 |
| Accruals ratio | −11.0% | 32.5% | −2.5% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Pass |
| Cash from operations is positive | Fail | Fail | Pass |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Fail | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | Fail |
| Revenue rose relative to assets | — | — | Pass |
| F-score | — | — | — |
Compare
Put CorMedix side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| CorMedix | FY25 | 617.0% | 48.2% | 55.4% | — | −0.9x | — | |
| Evolus | FY25 | 11.6% | −11.0% | −15.4% | −47.2% | — | 2 | Compare |
| Ironwood Pharmaceuticals | FY25 | −15.7% | 33.3% | 42.9% | — | — | — | Compare |
| Rigel Pharmaceuticals | FY25 | 64.2% | 42.6% | — | 91.3% | −0.8x | 7 | Compare |
| Xeris Biopharma | FY25 | 43.7% | 8.5% | — | 19.6% | 4.2x | 7 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | 44 | 312 |
| Revenue growth | 6.7% | 47.0% | 30.5% | −34.1% | −15.6% | −20.2% | −65.7% | — | — | 617.0% |
| Gross profit | −0 | 0 | 0 | −0 | 0 | 0 | 0 | — | 40 | 276 |
| Research and development | 16 | 24 | 19 | 11 | 13 | 13 | 11 | 13 | 4 | 19 |
| Operating income | −25 | −33 | −27 | −21 | −27 | −29 | −31 | −49 | −22 | 150 |
| Net income | −25 | −33 | −27 | −16 | −22 | −28 | −30 | −46 | −18 | 163 |
| Diluted EPS (US$) | −3.25 | −3.00 | −1.51 | −1.80 | −0.77 | −0.75 | −0.74 | −0.91 | −0.30 | 2.04 |
| Diluted shares (millions) | 8 | 11 | 18 | 24 | 29 | 38 | 40 | 51 | 59 | 80 |
| Cash flow | ||||||||||
| Cash from operations | −22 | −29 | −24 | −15 | −22 | −21 | −24 | −38 | −51 | 175 |
| Capital expenditure | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 |
| Free cash flow | −22 | −29 | −24 | −15 | −22 | −23 | −25 | −39 | −51 | 173 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 308 |
| Stock-based compensation | 1 | 2 | 1 | 2 | 2 | 5 | 4 | 6 | 6 | 14 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 20 | 12 | 18 | 28 | 46 | 66 | 59 | 76 | 52 | 148 |
| Debt incl. finance leases | — | 0 | 6 | — | — | — | — | — | — | 1 |
| Total assets | 22 | 14 | 19 | 30 | 49 | 69 | 62 | 82 | 119 | 826 |
| Total liabilities | 4 | 6 | 14 | 6 | 5 | 6 | 7 | 12 | 34 | 421 |
| Shareholders' equity | 18 | 7 | 5 | 24 | 44 | 63 | 55 | 70 | 85 | 405 |
| Margins and ratios | ||||||||||
| Gross margin | −63.6% | 65.1% | 7.7% | −31.8% | 14.4% | 22.0% | 94.3% | — | 92.7% | 88.5% |
| Operating margin | −11,048.8% | −9,997.4% | −6,250.4% | −7,416.3% | −11,378.4% | −15,417.5% | −46,819.9% | — | −51.4% | 48.2% |
| Net margin | −10,996.5% | −10,023.5% | −6,242.4% | −5,801.3% | −9,207.7% | −14,774.7% | −45,409.9% | — | −41.2% | 52.3% |
| Free cash flow margin | −9,961.5% | −8,726.6% | −5,525.7% | −5,326.6% | −9,229.7% | −11,826.2% | −37,573.5% | — | −116.7% | 55.4% |
| Rule of 40 (growth + FCF margin) | −9,954.8% | −8,679.7% | −5,495.2% | −5,360.8% | −9,245.2% | −11,846.4% | −37,639.3% | — | — | 672.5% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | −95.1% | −264.0% | −442.5% | −115.0% | −64.9% | −52.7% | −50.4% | −74.0% | −23.2% | 66.6% |
| Return on assets | −83.5% | −186.7% | −166.2% | −68.0% | −55.9% | −47.7% | −45.4% | −64.3% | −17.9% | 34.5% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | −0.9x |